The Week in Review: February 23 – March 2, 2018

Friday, March 2, 2018 News Recap: Canada: Shifting from concern to crisis: 1 in 4 Canadians may be affected by liver disease. Recent indicators gathered by the Canadian Liver Foundation (CLF) show that an increased prevalence of liver diseases including non-alcoholic fatty liver disease (NAFLD), chronic hepatitis B & C, and liver cancer are why in just ten years, the statistic that was once 1 in 10, is now 1 in 4. Ontario Expands Patient Acce...

Large Study Confirms DAAs Protect Against HCC When SVR Achieved

Patients with hepatitis C who are successfully treated with direct-acting antiviral agents experience a dramatic reduction in their risk for liver cancer, new data show. However, the decrease is much lower for those diagnosed with cirrhosis before starting a DAA. The risk for liver cancer after a sustained virologic response (SVR) is achieved is still above zero. As a result, the new data point to the need for cancer surveillance in at least some patients

The Week in Review: October 27 – November 4, 2017

Friday, November 4, 2017 News Recap: Access to Treatment Hepatitis C could be eliminated in Canada, but drug prices, screening barriers stand in the way – Most of the 70 million patients infected with hepatitis C worldwide could be cured for $50 US each Many countries — including Canada — have committed to a global goal of eliminating hepatitis C by 2030. But new data released at the summit in Brazil shows that only nine countries are on track to me...

Curing hepatitis C with DAAs linked to 71% reduction in liver cancer

People who achieved a sustained response to hepatitis C treatment lowered their risk of hepatocellular carcinoma by around 70%, regardless of whether they were treated with new direct-acting antivirals (DAAs) or older interferon-based therapy, according to study results presented at the 2017 AASLD Liver Meeting last week in Washington, DC. "It doesn’t matter how you eradicate hepatitis C, you get a similar reduction in liver cancer," George Ioannou of the

The Week in Review: September 1 – September 8, 2017

Friday, September 8, 2017 News Recap: She thought her mystery ailment was cancer, but bloodwork revealed a surprise This is an amazing story ...but it could happen to anyone, and we know this because we hear these kinds of stories often. This is why it is so important that Boomers be tested for hepatitis C. Gail Wells got really sick and nobody could figure out why. They looked for cancer, for multiple sclerosis, for vitamin deficiencies, and then s...

Risk for hepatocellular carcinoma after HCV antiviral therapy with DAAs: case closed?

This new article by Raoel Maan and Jordan J. Feld will be published in Gastroenterology  (2017), doi: 10.1053/j.gastro.2017.08.052  It is in press, but courtesy of HCV New Drugs we are able to provide you with a pdf of the accepted manuscript. Several studies of patients treated with interferon -based therapy nicely documented that the risk for hepatocellular carcinoma (HCC) was markedly lower in patients who achieved SVR compared to those without SVR. 5-

High Rates of Hepatocellular Carcinoma After Hepatitis C Treatment

NEW YORK (Reuters Health) - Patients treated with direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV)-related cirrhosis appear to have high rates of hepatocellular carcinoma (HCC) – Will Boggs MD. "If these findings are confirmed from other centers, studies are suggested to examine mechanisms of these findings," Dr. Ashwani Singal from University of Alabama at Birmingham told Reuters Health by email. Some studies have shown unexpectedly h

The Week in Review: Nov 11 – Nov 18, 2016

Friday, November 18, 2016 AASLD, 2016: Focus on Liver Cancer and DAAs This year at The Liver Meeting® — held by the American Association for the Study of Liver Diseases (AASLD 2016) — there were a lot of presentations on Liver Cancer (HCC) and the new DAAs.  Over the past decade, the prevalence of cirrhosis has increased by almost 40 percent among people with hepatitis C (HCV) in the United States. The proportion of hepatitis C patients with cirrhosi...

Is There an Increased Risk of Cancer After Taking Direct-Acting Antiviral Medication?

BOSTON, Nov. 11, 2016 /PRNewswire/ -- A new study presented this week at The Liver Meeting® — held by the American Association for the Study of Liver Diseases — found patients with hepatitis C who take direct-acting antiviral medication are at no higher risk for developing liver cancer than those who do not take the medication. However, they might be at an increased for more aggressive, infiltrative patterns of cancer, should they develop it. "Dat...